, Columnist
With Biosimilars, Big Pharma Fights Itself
Competition for complex, expensive blockbusters will keep rising.
This article is for subscribers only.
Fighting yourself is a losing battle.
A long-cherished hope of some companies that make expensive biologic medications -- complex drugs made with living cells -- is that they were relatively safe from competition because biologics are tougher to copy and replace than traditional drugs. That's looking a bit less true every day.